Pharmacokinetics of hederacoside C, an active ingredient in AG NPP709, in rats. (November 2013)

• Record Type: Journal Article
• Authors: Kim, Ju Myung; Yoon, Ji Na; Jung, Ji Won; Choi, Hye Duck; Shin, Young June; Han, Chang Kyun; Lee, Hye Suk; Kang, Hee Eun
• Is Part Of: Xenobiotica. Volume 43:Number 11(2013:Nov.)
• Page Start: 985
• Page End: 992
• Publication Date: 2013-11
• Subjects: Metabolism -- Periodicals; Drugs -- Physiological effect -- Periodicals; Food additives -- Periodicals; Chemicals -- Physiological effect -- Periodicals; Biochemistry -- Periodicals; Pharmaceutical Preparations -- metabolism -- Periodicals; Metabolism -- Periodicals; 574.133
• DOI: 10.3109/00498254.2013.788231
• Languages: English
• ISSNs: 0049-8254

Abstract

<abstract> <title>Abstract</title> <p>1. Hederacoside C (HDC) is one of the active ingredients in <italic>Hedera helix</italic> leaf extract (Ivy Ex.) and AG NPP709, a new botanical drug to treat acute respiratory infection and chronic inflammatory bronchitis. However, information regarding its pharmacokinetic properties remains limited.</p> <p>2. Here, we report the pharmacokinetics of HDC in rats after intravenous administration of HDC (3, 12.5, and 25 mg/kg) and after oral administration of HDC, Ivy Ex., and AG NPP709 (equivalent to 12.5, 25, and 50 mg/kg HDC).</p> <p>3. Linear pharmacokinetics of HDC were identified upon its intravenous administration at doses of 3–25 mg/kg. Intravenous administration of HDC results in relatively slow clearance (1.46–2.08 mL/min/kg) and a small volume of distribution at steady state (138–222 mL/kg), while oral administration results in a low absolute oral bioavailability (<italic>F</italic>) of 0.118–0.250%. The extremely low <italic>F</italic> of HDC may be due to poor absorption of HDC from the gastrointestinal (GI) tract and/or its decomposition therein.</p> <p>4. The oral pharmacokinetics of HDC did not differ significantly among pure HDC, Ivy Ex., and AG NPP709.</p> </abstract>